John Ryan asks Thomas Marwick about his new study, which found that the most reproducible technique for serial assessment of LVEF is the noncontrast 3D echocardiogram.
Dr. Valentin Fuster answers questions about the FREEDOM trial, which shows that diabetics with multivessel disease had lower rates of death and MI with CABG than with PCI.
Dr. Johnson answers questions about her research group’s study of undiagnosed hypertension in younger adults.
The principal investigator of the MADIT-RIT trial comments on the clinical implications of his study group’s research.
An ARCTIC trial investigator discusses possible reasons why antiplatelet-drug and dosing adjustments, guided by platelet-function testing, did not improve clinical outcomes for stented patients.
Younger, healthier treatment-naive patients with a-fib can be offered initial ablation therapy, although drug therapy remains the default, according to the authors of this recent study in the NEJM.
Morten Lamberts, MD, lead investigator of a recent registry study of various combinations of antithrombotic agents in patients with AF and CAD, answers John Ryan’s questions about the study and its implications.
Paul Ridker discusses findings from the Emerging Risk Factors Collaboration showing that C-reactive protein provides incremental risk information comparable to that of total cholesterol and HDL cholesterol.
Dr. Sripal Bangalore discusses his JAMA study, which found beta-blocker use was not associated with a reduced rate of cardiovascular eventsin patients who have, or are at risk for, stable coronary artery disease.
Dr. Deepak Bhatt ponders the clinical implications of two studies suggesting that early discontinuation of dual antiplatelet therapy is safe — and concludes that the findings will probably not change his practice.
